Noribogaine in the treatment of pain and drug addiction
The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.
1. A method of treating a patient to alleviate nociceptive pain in the absence of the treatment of drug dependence or drug abuse comprising: administering systemically to said patient a pharmaceutical composition consisting essentially of an effective amount of noribogaine or its pharmaceutically acceptable salt to said patient effective to reduce or eliminate said nociceptive pain in said patient, wherein the noribogaine or its salt is the sole analgesic agent administered.
2. The method of claim 1 , wherein said noribogaine or its salt is administered to said patient at a dose of between 0.1 mg and 100 mg per kg of body weight.
3. The method of claim 2 , wherein said noribogaine or its salt is administered at a dose of between 1.0 mg and 30 mg per kg of body weight.
4. A method of treating a patient to alleviate nociceptive pain in the absence of the treatment of drug dependency or drug abuse, comprising:
a) administering systemically to said patient an amount of noribogaine or its pharmaceutically acceptable salt; and
b) concomitantly administering systemically to said patient an amount of one or more opioid antagonists; wherein said respective amounts of noribogaine and said one or more opioid antagonists are effective to reduce or eliminate nociceptive pain in said patient, and wherein the noribogaine or its salt is the sole analgesic administered.
5. The method of claim 4 , wherein said opioid antagonist is naloxone, administered to said patient at a dose between 0.05 mg and 0.5 mg for each mg of noribogaine.
6. The method of claim 4 , wherein said opioid antagonist is naltrexone, administered to said patient at a dose of between 0.05 mg and 0.5 mg for each mg of noribogaine.
7. The method of claim 4 , wherein said noribogaine and said opioid antagonist are administered transdermally.
8. The method of claim 4 , wherein said noribogaine or its salt is administered to said patient at a dose of between 0.1 mg and 100 mg per kg of body weight.
9. The method of claim 8 , wherein said noribogaine or its salt is administered at a dose of between 1.0 mg and 30 mg per kg of body weight.